Shalini Arunogiri 1 , Nicholas A Keks 2 , Judy Hope 3 Show Affiliations »
Abstract
OBJECTIVE: There has been widespread interest from the public and media in the potential of ketamine as a novel treatment for depression. This paper reviews whether current evidence supports the use of ketamine for the clinical treatment of depression. CONCLUSIONS: Clinical trials have investigated the use of intravenous ketamine for the treatment of depressive symptoms over the past 15 years. However, there remain many unanswered questions regarding its effectiveness, safety, and the route, dose and regimen for repeated administration. Experts have also raised concerns regarding ketamine's adverse effects, abuse potential and the risk of addiction. At this stage, the use of ketamine in the treatment of depression remains in the realm of research settings. © The Royal Australian and New Zealand College of Psychiatrists 2016.
OBJECTIVE: There has been widespread interest from the public and media in the potential of ketamine as a novel treatment for depression . This paper reviews whether current evidence supports the use of ketamine for the clinical treatment of depression . CONCLUSIONS: Clinical trials have investigated the use of intravenous ketamine for the treatment of depressive symptoms over the past 15 years. However, there remain many unanswered questions regarding its effectiveness, safety, and the route, dose and regimen for repeated administration. Experts have also raised concerns regarding ketamine 's adverse effects, abuse potential and the risk of addiction. At this stage, the use of ketamine in the treatment of depression remains in the realm of research settings. © The Royal Australian and New Zealand College of Psychiatrists 2016.
Entities: Chemical
Disease
Keywords:
depression; ketamine; pharmacotherapy
Mesh： See more »
Substances： See more »
Year: 2016
PMID： 26849894 DOI： 10.1177/1039856216629839
Source DB: PubMed Journal: Australas Psychiatry ISSN： 1039-8562 Impact factor: 1.369